The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to reverse a prior High Court ruling that granted a patent win to their rival ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine. Siding with Moderna, an American pharmaceutical firm ...

The US government has agreed to pay Pfizer and BioNTech $1.95 billion for 100 million doses of their COVID-19 vaccine if it ...

LONDON, July 10 (Reuters) - Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in ...

Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...